$775.63
1.01% today
Nasdaq, Dec 06, 05:13 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$767.90
-61.53 7.42% 1M
-237.97 23.66% 6M
-110.39 12.57% YTD
-53.00 6.46% 1Y
+142.90 22.86% 3Y
+399.56 108.48% 5Y
+344.67 81.44% 10Y
Nasdaq, Closing price Thu, Dec 05 2024
+13.64 1.81%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $84.38b
Enterprise Value $77.29b
P/E (TTM) P/E ratio 19.00
EV/FCF (TTM) EV/FCF 22.47
EV/Sales (TTM) EV/Sales 5.58
P/S ratio (TTM) P/S ratio 6.09
P/B ratio (TTM) P/B ratio 2.88
Revenue growth (TTM) Revenue growth 5.72%
Revenue (TTM) Revenue $13.85b
EBIT (operating result TTM) EBIT $4.14b
Free Cash Flow (TTM) Free Cash Flow $3.44b
Cash position $9.80b
EPS (TTM) EPS $40.41
P/E forward 19.80
P/S forward 5.96
EV/Sales forward 5.46
Short interest 1.71%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Analyst Opinions

29 Analysts have issued a Regeneron Pharmaceuticals forecast:

19x Buy
66%
9x Hold
31%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
66%
Hold
31%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13,847 13,847
6% 6%
100%
- Direct Costs 2,391 2,391
13% 13%
17%
11,456 11,456
4% 4%
83%
- Selling and Administrative Expenses 2,435 2,435
14% 14%
18%
- Research and Development Expense 4,414 4,414
13% 13%
32%
4,608 4,608
7% 7%
33%
- Depreciation and Amortization 470 470
15% 15%
3%
EBIT (Operating Income) EBIT 4,138 4,138
9% 9%
30%
Net Profit 4,655 4,655
17% 17%
34%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
Seeking Alpha
about 21 hours ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations & Strategic Analysis Chris Fenimore - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay, let's go ahead and ...
Neutral
GlobeNewsWire
2 days ago
LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws.
Neutral
GlobeNewsWire
3 days ago
BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 13,450
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today